前性痴呆症,当前的诊断和治疗强调自然产品:一篇评论
Zulfa Nooreen1, Fariha Sumayya2, Pranay Wal1
1PSIT-Pranveer Singh Institute of Technology (Pharmacy), Bhauti Kanpur Uttar Pradesh -209305, India.
Current aging science
|March 21, 2025
概括
前性痴呆症 (FTD) 是一种神经退行性疾病,影响行为和沟通. 自然化合物显示出有希望的FTD症状管理与更少的副作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 前性痴呆症 (FTD) 是一组影响前和叶的大脑疾病,影响人格,行为和沟通.
- FTD是由异常的蛋白质聚合物,遗传学和突变引起的,通常影响45-65岁的个体.
- 目前,没有FDA批准的FTD药物治疗方法,尽管有诊断生物标志物可供使用.
研究的目的:
- 审查FTD的风险因素,发病,病理生理学,诊断标准和治疗方法.
- 专注于自然产品和植物成分在FTD管理中的应用.
主要方法:
- 通过使用在线数据库进行了全面的文献搜索:SciFinder,Medline,Pubmed,Google Scholar和Scopus.
- 该审查综合了FTD治疗合成和天然药物的信息.
主要成果:
- 对FTD管理的药理和非药理干预措施进行了记录.
- 抗胆化酶,抗炎和抗氧化剂化合物越来越多地因其在FTD中的潜力而被认可.
- 草药和植物成分提供潜在的治疗益处,具有有利的副作用.
结论:
- 目前的治疗方法旨在暂时缓解FTD症状并减缓疾病的进展.
- 自然产品和植物成分为开发有效的FTD疗法提供了有希望的途径.
- 对草药的进一步研究可能会导致对痴呆症患者的副作用降低的治疗方法.
更多相关视频
相关概念视频
Alzheimer's Disease: Treatment
139
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
139
Alzheimer's Disease: Overview
405
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
405
Dementia
81
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
81
Parkinson's Disease: Treatment
170
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
170
Parkinson's Disease: Overview
405
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
405
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
87
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
87


